Drug profile · INN
somapacitan
SOGROYA
somapacitan (SOGROYA) is a growth hormone receptor agonist.
EMA: approved NMPA: clinical trials Systemic hormonal preparations (H01) H01AC07
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — somapacitan
- Class
- Systemic hormonal preparations (H01)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
somapacitan (SOGROYA) is a growth hormone receptor agonist.
Reviewed by James Park Regulatory Affairs Editor Last reviewed Jun 8, 2026
Key facts
INN somapacitan
Brand SOGROYA
Mechanism Growth hormone receptor agonist
Target Growth hormone receptor
Therapeutic class Systemic hormonal preparations (H01)
ATC code H01AC07
Mechanism of action
Growth hormone receptor agonist
Primary target: Growth hormone receptor
Approval history
Regional status spokes: EMA status · APAC status
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is somapacitan?
somapacitan (SOGROYA) is a growth hormone receptor agonist.
What is the brand name for somapacitan?
SOGROYA is a marketed brand name for somapacitan. Check FDA Drugs@FDA for the current US label holder and prescribing information.